Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia

Model scores of the 29,894 trials active now.

Model score 25% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (283 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-05-05. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerpulmonaryleukemiaventricularheart
  Phrases that lowered it: subjectseffectpatients whomalelong
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports with a death: 36.4% (raises risk) · Drug's FDA history
• Responsible party: sponsor investigator (raises risk) · Design
• Phase: 1/2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 96.0% (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 3 (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Minimum age: not given (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Design: sequential (raises risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• PKC412 and 5-Azacytidine NCT01202877 · started 2011 · scored riskier than 99% of active trials completed
• Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia. NCT03379727 · started 2018 · scored riskier than 58% of active trials completed
• Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation NCT02634827 · started 2015 · scored riskier than 89% of active trials terminated
• Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia NCT01846624 · started 2013 · scored riskier than 93% of active trials terminated
• Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia NCT01130662 · started 2010 · scored riskier than 91% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.